/
RSS Feed
In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin, on news from the 2026 Tandem Meetings, including updates on dual-targeted CAR T-cell results in CLL and interim phase 2 data on zamtocabtagene autoleucel (zamto-cel) in in transplant-ineligible patients with DLBCL.
Of dual-targeting CAR-T cell therapies, he said, “I think this is the next iteration in CAR. Zamtocabtagene is one of four 20/19 CARs under development and if you look at the data for all of them, they look to be highly efficacious, better than our standard CD19-CAR.”
